CooperCompanies (COO) handed the market two gut punches at once last Wednesday. Shares plunged about 15% in after-hours trading after the medical device company reported third-quarter results that missed revenue expectations and issued fourth-quarter and full-year guidance below analyst estimates. By Thursday’s close (September 10, 2026), the stock had shed about 18.1% on the session. The proximate causes were a revenue miss and a failed strategic review, but the options opportunity lives in the gap between what the market is pricing and what management actually said on the earnings call.
COO reported non-GAAP diluted EPS of $1.15 for the fiscal third quarter ended July 31, 2026, beating the analyst consensus of $1.12, though revenue of $1.066 billion fell short of the roughly $1.1 billion estimate. The company also announced it would retain CooperSurgical after completing its strategic review process, concluding that offers received were not in shareholders’ best interest. Investors who had assigned meaningful probability to a CooperSurgical sale got nothing. That double disappointment is legitimate. What is less legitimate is treating the CooperVision shortfall as a structural demand collapse.
The Story Behind the Trade
CEO Al White was asked directly whether the entire CooperVision revision was inventory-related. His answer: “Yes, Jon, it’s all destock. So the consumption in the U.S. market here has been running pretty steady all year in the mid-single digits. It was — it did in Q3, and it did in the first month of this quarter. So I would expect consumption to remain as is. Meaning the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory. That’s it.” That is about as explicit as a CEO gets on an earnings call.
Management attributed elevated inventory to several factors, including purchases ahead of price increases, customer consolidation, IT upgrades and inventory associated with recently won private-label contracts. White also said the company has “ring-fenced” the issue, pointing to the mix of products involved and reiterating that the company expects the bulk of the inventory actions to be behind it in fiscal Q4 as it heads into fiscal 2027.
The market sold this as demand destruction. Management says it is inventory logistics. That disagreement is where the trade lives.
Technical and Fundamental Alignment
COO closed at $54.58 on September 10, with a 52-week range of $51.01 to $89.83. The stock is pressing its 52-week floor. Meanwhile, the underlying business still generates real cash: GAAP EPS was boosted by a $307.2 million benefit from a favorable U.K. tax examination, and free cash flow increased 66% to $273.0 million. The board also expanded its share-repurchase authorization from $2 billion to $3 billion. A company expanding buybacks while sitting near a 52-week low is sending a signal worth hearing.
The analyst community was brutal. William Blair downgraded COO to Market Perform from Outperform on September 10, 2026. Stifel lowered its price target to $70 from $85, maintaining a Buy rating. William Blair noted the shares were trading at roughly a 25% discount to peers on a 2027 price-to-earnings ratio of approximately 11.5 times. Deep valuation discounts after panic-driven selling are the raw material of asymmetric options plays.
Options Perspective
COO was flagged premarket on September 10 as one of the options with increasing implied volatility, meaning premiums spiked into and through the event. That elevated IV is now working in favor of a debit spread buyer who moves in after the crush. The strategy here is a bull call spread targeting the $60 to $70 range in COO with a December expiration, giving the destocking cleanup time to show up in Q4 numbers and allowing fiscal 2027 guidance to reset expectations. You pay a defined premium, cap the upside at the spread’s upper strike, and eliminate the need to be right on the exact date of recovery.
The key risk is straightforward: if destocking bleeds into early fiscal 2027, the thesis delays and time decay eats the position. The near-term test is whether CooperVision’s inventory correction ends in Q4 or spills into fiscal 2027. Position sizing matters. This is a thesis trade, not a conviction bet, and it should be sized accordingly.
The Beast Verdict
Management said the U.S. contact lens market is still growing at a mid-single-digit pace and that CooperVision should be able to grow within the market’s 4% to 6% range once destocking is complete. If that proves accurate, the current price embeds a permanent demand impairment that does not exist. The CooperSurgical news is a genuine negative. The CooperVision story is a temporary one being priced as permanent. A December bull call spread on COO captures that distinction with risk defined from the moment the trade is on.
